MedTech Dive: J&J’s Impella heart pump shows no patient benefit in 2 trials MedPage Today on MSN: Impella flops for acute coronary syndrome patients not in shock Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ benefits, spanning specific cases in patients with blockages in their coronary ... In the STEMI Door-to-Unload trial, use of Impella missed the mark in patients with anterior MI without cardiogenic shock. DANVERS, Mass., Oct.

Understanding the Context

26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the first patient treated with the Impella ... Business Insider: Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.